Racura Oncology Ltd
Company Profile
Business description
Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.
Contact
1 Macquarie Place
Level 36
Gateway
SydneyNSW2000
AUST: +61 280513043
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,173.60 | 36.60 | -0.40% |
| CAC 40 | 8,262.70 | 11.87 | -0.14% |
| DAX 40 | 24,154.47 | 87.77 | 0.36% |
| Dow JONES (US) | 48,578.72 | 115.00 | 0.24% |
| FTSE 100 | 10,589.99 | 30.41 | 0.29% |
| HKSE | 26,394.26 | 521.94 | 2.02% |
| NASDAQ | 24,102.70 | 86.69 | 0.36% |
| Nikkei 225 | 59,518.34 | 1,640.95 | 2.84% |
| NZX 50 Index | 13,105.67 | 39.61 | 0.30% |
| S&P 500 | 7,041.28 | 18.33 | 0.26% |
| S&P/ASX 200 | 8,955.00 | 56.40 | -0.63% |
| SSE Composite Index | 4,055.55 | 28.34 | 0.70% |